Cell Surface Markers and their Targeted Drugs in Breast Cancer

Abstract

Breast cancer is the most common cancer affecting women's health, and its incidence rate is continuously increasing. With the development of immunohistochemistry and gene expression microarray technology, the study on breast cancer has gradually advanced, contributing to the development of targeted therapy for breast cancer. At present, the popular breast cancer cell surface markers includeG protein-coupled estrogen receptor 1 (GPER-1), human epidermal growth factor receptor 2 (HER-2), epidermal growth factor receptor (EGFR), c-mesenchymal-epithelial transition factor (CMet), folate receptor-α (FRα), integrin, programmed death-ligand 1 (PD-L1), trophoblast cell surface antigen 2 (Trop-2), etc. Targeted drugs for breast cancer cell surface markers mainly include antibody drugs and small molecule inhibitor drugs, which exert anti-tumor activity by targeting receptors or ligands. This review summarizes the surface markers of breast cancer cells and their targeted drugs, hoping to provide new ideas for breast cancer targeted therapy.

Keywords: Breast cancer; cell surface markers; drugs; monoclonal antibodies; small molecule inhibitors; targeted therapy.